{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-120673","form_type":"8-K","ticker":"SNDX","cik":"0001395937","company_name":"Syndax Pharmaceuticals Inc","filed_at":"2024-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.333234+00:00","generated_at":"2026-05-30T05:54:43.963201+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Syndax sells 13.8% royalty on Niktimvo (axatilimab) to Royalty Pharma for $350M upfront","bullets":["Royalty Pharma acquires right to 13.8% of net sales of Niktimvo (axatilimab) in US and territories.","Upfront payment of $350M; aggregate payments to Royalty Pharma capped at $822.5M.","Royalty rate subject to adjustments based on future aggregate net sales.","Syndax retains repurchase right upon change of control; events of default trigger mandatory repurchase at cap."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-120673","json":"https://secwatch.observer/filing/0000950170-24-120673.json","markdown":"https://secwatch.observer/filing/0000950170-24-120673.md","text":"https://secwatch.observer/filing/0000950170-24-120673.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1395937/000095017024120673/0000950170-24-120673-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1395937/000095017024120673/sndx-20241104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T05:54:43.963201+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}